Atosiban Acetate Powder CAS No：90779-69-4

Product Introduction

Product Name: Atosiban Acetate Product content: ≥ 98% CAS No：90779-69-4 Detection method: HPLC Active ingredient: cyclic nonapeptide Molecular formula: C45H71N11O14S2 Molecular weight: 994.19 Product Description: White to off white crystalline powder, easily soluble in water Product usage: scientific research, pharmaceuticals Product packaging: 1 mg -10 g; Optional 1g bottle, 10g bottle, 50g bottle, etc Product storage: -20 ℃, sealed in the dark (dry); Partial suggestion: Refrigeration at 2-8 ℃ Shelf life: 24 months Declaration of Use: This product is intended for industrial use or scientific research only.

Products Description 

Shaanxi Sunrise Atosiban Acetate Product Overview

Shaanxi Sunrise focuses on high-quality pharmaceutical grade peptide raw materials. Atosiban acetate (CAS 90779-69-4/acetic acid form 914453-95-5) produced strictly following the quality control system has excellent purity and stability. This product adopts advanced synthesis and purification processes, and the purity of conventional batches can be verified by HPLC to be over 98%. It can also provide high specification products with a purity of ≥ 99%, accurately meeting the stringent requirements of pharmaceutical research and production. The product is a white to off white crystalline powder with excellent water solubility (≥ 50 mg/mL) and high consistency between batches, ensuring reliable reproducibility of experimental or production formulas.

Shaanxi Sunrise Pharmaceutical Co., Ltd. is committed to providing customers with stable, compliant, and reliable high-quality acetic acid atosiban raw materials. We are your solid partner from research and development to production

Products Function

Atosiban acetate is a highly selective uterine contraction inhibitor that competitively antagonizes the oxytocin receptor (OXTR) and vasopressin V1A receptor (V1AR) on uterine smooth muscle, blocking the oxytocin and vasopressin mediated uterine contraction signaling pathway and inhibiting uterine contractions. Its core functions include:

1. Rapid inhibition of uterine contractions: Significant reduction in uterine contraction frequency and intensity within 10 minutes after intravenous administration

2. Maintaining uterine stillness: prolonging pregnancy time and providing a critical window period for promoting fetal lung maturation treatment

Products Aplication

1. Clinical indications

Suitable for pregnant women between 24-33 weeks of gestation who meet the following conditions, delaying imminent preterm birth, as shown below

Uterine contraction indicators, uterine contraction status, fetal monitoring

2. Special application scenarios

Assisted reproductive technology (ART), alternative to traditional uterine contraction inhibitors

Mechanism of action

1. Receptor level antagonism

Target binding: Competitive binding of OXTR and V1AR in the uterine muscle layer, decidua, and membranes, blocking the effects of endogenous oxytocin and vasopressin.

Signal pathway inhibition:

● Inhibiting Gq protein conjugation → reducing inositol triphosphate (IP3) production → blocking sarcoplasmic reticulum calcium ion release;

● Inhibition of voltage-gated calcium channel opening → reduction of extracellular calcium influx

2. Uterine specific effects

Smooth muscle relaxation, prostaglandin inhibition

Toxicological conclusion

● Hort term toxicity:

Dogs/rats were intravenously injected with 10 times the human dose for 3 months, and no organ pathological damage was observed.

● Reproductive toxicity:

Exposure to fetal sheep did not cause malformations; No evidence of genetic mutation or carcinogenicity (Ames test/chromosomal aberration test negative)

Key conclusions

Acetate atosiban, as a uterine specific uterine contraction inhibitor, achieves premature delivery delay through precise receptor antagonism mechanism. Its cardiovascular safety is significantly better than traditional drugs, and there is no clear fetal toxicity. Strictly following the indications and dosing regimen is the core prerequisite for ensuring efficacy.